JP2018512435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512435A5 JP2018512435A5 JP2017553974A JP2017553974A JP2018512435A5 JP 2018512435 A5 JP2018512435 A5 JP 2018512435A5 JP 2017553974 A JP2017553974 A JP 2017553974A JP 2017553974 A JP2017553974 A JP 2017553974A JP 2018512435 A5 JP2018512435 A5 JP 2018512435A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- amino acid
- antibody
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147853P | 2015-04-15 | 2015-04-15 | |
| US62/147,853 | 2015-04-15 | ||
| US201562234899P | 2015-09-30 | 2015-09-30 | |
| US62/234,899 | 2015-09-30 | ||
| US201562261528P | 2015-12-01 | 2015-12-01 | |
| US62/261,528 | 2015-12-01 | ||
| PCT/US2016/027774 WO2016168613A1 (en) | 2015-04-15 | 2016-04-15 | Methods of increasing strength and functionality with gdf8 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512435A JP2018512435A (ja) | 2018-05-17 |
| JP2018512435A5 true JP2018512435A5 (enExample) | 2019-05-09 |
| JP6877357B2 JP6877357B2 (ja) | 2021-05-26 |
Family
ID=55809250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553974A Active JP6877357B2 (ja) | 2015-04-15 | 2016-04-15 | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10934349B2 (enExample) |
| EP (1) | EP3283519A1 (enExample) |
| JP (1) | JP6877357B2 (enExample) |
| KR (2) | KR20170135967A (enExample) |
| CN (1) | CN107771081A (enExample) |
| AU (1) | AU2016249015B2 (enExample) |
| CA (1) | CA2982810A1 (enExample) |
| EA (1) | EA201792298A1 (enExample) |
| HK (1) | HK1250236A1 (enExample) |
| IL (1) | IL255010B2 (enExample) |
| MA (1) | MA49661A (enExample) |
| MX (1) | MX2017013267A (enExample) |
| WO (1) | WO2016168613A1 (enExample) |
| ZA (1) | ZA201707550B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| NZ789269A (en) * | 2016-06-13 | 2026-01-30 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| MX2020008991A (es) * | 2018-03-01 | 2020-12-10 | Regeneron Pharma | Metodos para alterar la composicion corporal. |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
| CN111303280B (zh) * | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
| CN117083065A (zh) | 2020-10-30 | 2023-11-17 | 庆应义塾 | 肌肉减少症相关疾病等的新颖治疗和预防 |
| JPWO2023145735A1 (enExample) | 2022-01-25 | 2023-08-03 | ||
| EP4638496A1 (en) | 2022-12-22 | 2025-10-29 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2026008041A1 (zh) * | 2024-07-04 | 2026-01-08 | 江苏恒瑞医药股份有限公司 | 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1910220A (en) * | 1931-10-21 | 1933-05-23 | Kremser Alois | Mechanically operated gate |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| JP4544742B2 (ja) | 1998-05-06 | 2010-09-15 | メタモーフイクス・インコーポレーテツド | Ｇｄｆ−８の阻害による糖尿病の処置法 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| TR200400621T2 (tr) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
| US6670140B2 (en) | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| EP1699820A2 (en) | 2003-12-31 | 2006-09-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| EP3006039B1 (en) | 2004-03-02 | 2021-01-06 | Acceleron Pharma Inc. | Alk7 polypeptides for use in promoting fat loss |
| ATE557042T1 (de) | 2004-03-23 | 2012-05-15 | Lilly Co Eli | Anti-myostatin-antikörper |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| KR101443050B1 (ko) | 2005-05-06 | 2014-09-22 | 지모제넥틱스, 인코포레이티드 | Ｉｌ-31 단클론성 항체 및 사용법 |
| EP1773041A1 (en) | 2005-07-21 | 2007-04-11 | Chao-Hung Wu | Audio/video data transmission system using the internet to interconnect telephones |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| EP1951756B1 (en) | 2005-10-06 | 2015-01-07 | Eli Lilly And Company | Anti-myostatin antibodies |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| WO2007067616A2 (en) | 2005-12-06 | 2007-06-14 | Amgen Inc | Uses of myostatin antagonists |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| CN101522707B (zh) | 2006-08-03 | 2013-08-28 | 莫约斯汀医疗有限公司 | 肌肉生长抑制素拮抗剂 |
| BRPI0716249A2 (pt) | 2006-09-05 | 2013-09-03 | Lilly Co Eli | anticorpos antimiostatina |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| CN101910150B (zh) | 2007-11-05 | 2013-09-18 | 诺瓦提斯公司 | 作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物 |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| SG187867A1 (en) | 2010-08-16 | 2013-03-28 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| SG194802A1 (en) | 2011-05-16 | 2013-12-30 | Genzyme Corp | Induction of immune tolerance by using methotrexate |
| DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| KR101704893B1 (ko) * | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| HK1219280A1 (zh) * | 2013-08-14 | 2017-03-31 | Novartis Ag | 治疗偶发性包涵体肌炎之方法 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| MX2020008991A (es) | 2018-03-01 | 2020-12-10 | Regeneron Pharma | Metodos para alterar la composicion corporal. |
-
2016
- 2016-04-15 KR KR1020177032792A patent/KR20170135967A/ko not_active Ceased
- 2016-04-15 IL IL255010A patent/IL255010B2/en unknown
- 2016-04-15 HK HK18109657.5A patent/HK1250236A1/zh unknown
- 2016-04-15 JP JP2017553974A patent/JP6877357B2/ja active Active
- 2016-04-15 WO PCT/US2016/027774 patent/WO2016168613A1/en not_active Ceased
- 2016-04-15 EA EA201792298A patent/EA201792298A1/ru unknown
- 2016-04-15 CA CA2982810A patent/CA2982810A1/en active Pending
- 2016-04-15 EP EP16718831.7A patent/EP3283519A1/en active Pending
- 2016-04-15 KR KR1020247027318A patent/KR20240128136A/ko active Pending
- 2016-04-15 MX MX2017013267A patent/MX2017013267A/es unknown
- 2016-04-15 US US15/099,701 patent/US10934349B2/en active Active
- 2016-04-15 AU AU2016249015A patent/AU2016249015B2/en active Active
- 2016-04-15 MA MA049661A patent/MA49661A/fr unknown
- 2016-04-15 CN CN201680035382.9A patent/CN107771081A/zh active Pending
-
2017
- 2017-11-08 ZA ZA2017/07550A patent/ZA201707550B/en unknown
-
2021
- 2021-01-14 US US17/149,540 patent/US12029788B2/en active Active
-
2024
- 2024-05-24 US US18/674,399 patent/US20240390489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512435A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2014533279A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2016501892A5 (enExample) | ||
| JP2016507470A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2018503361A5 (enExample) | ||
| JP2019523295A5 (enExample) | ||
| RU2015136392A (ru) | Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности | |
| JP2015517529A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| IL272674B2 (en) | Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation | |
| JP2013542194A5 (enExample) | ||
| JP2014534956A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| IL273678B2 (en) | Methods for treating allergy and improving allergen-specific immunotherapy by administering an IL-4R inhibitor | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2022536469A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2019528285A5 (enExample) | ||
| IL276921B1 (en) | Methods for altering body composition |